Your browser version may not work well with NCBI's Web applications. More information here...
1: Cardiol Rev. 2002 Sep-Oct;10(5):265-78. Links

Primary pulmonary hypertension and cor pulmonale.

Departments of Pulmonary Medicine, General Internal Medicine, and Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA.

Primary pulmonary hypertension and cor pulmonale represent forms of precapillary pulmonary hypertension due to intrinsic lung disease. In the case of primary pulmonary hypertension, this is due to disease of the pulmonary vasculature while cor pulmonale is related to diseases of the pulmonary vasculature, airways, or interstitium. Patients present with signs and symptoms of right ventricular dysfunction and low cardiac output including dyspnea, chest pain and peripheral edema. Therapy is directed at the underlying disease and may include supplemental oxygen for diseases causing chronic hypoxemia and anticoagulation for thrombotic disease. Vasodilator therapy has variable efficacy for pulmonary vascular disorders. Postacyclin by continuous infusion has been a major advance in the therapy of primary pulmonary hypertension and has prolonged survival and delayed the need for lung transplantation. Bosentan, an endothelin receptor blocking agent is the first oral medication approved for the therapy of pulmonary hypertension.

PMID: 12215190 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Bosentan (Tracleer® )

    Bosentan is used to treat pulmonary arterial hypertension (PAH, high blood pressure in the vessels that carry blood to the lungs). Bosentan may improve the ability to exercise and slow the worsening of symptoms in patien...